Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

Horizon Therapeutics seen worth up to $140/share in takeover

Stock Markets Dec 01, 2022 00:26
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
HZNP
-1.55%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Investing.com Staff

Several Wall Street analysts put pencil to paper after Horizon Therapeutics (NASDAQ:HZNP) said Tuesday evening that it was in "highly preliminary" takeover talks with Amgen Inc (NASDAQ:AMGN), Janssen Global Services, LLC (JNJ), and Sanofi (NASDAQ:SNY). A deal price as high as $140 per share was the high watermark discussed by at least two analysts.

Cowen analysts said that given their belief that Tepezza's previous pause was understandable and resolvable, they viewed the valuation as "meaningfully discounted.". As such they believe a transaction will occur. They believe at minimum a price above its all-time high (~$120) and potentially closer to their price target ($140) would be reasonable.

Meanwhile, BMO Capital analysts said historical M&A premiums suggest a fair range of ~$23-28B or $98-$118 per share implying a 25-50% premium on Tuesday's closing price. They see Amgen as the best strategic fit for a deal.

"Amgen has deal capacity for a $28B deal, likely a better strategic fit," the analysts commented. "As of 3Q22 earnings Amgen had cash on hand of $11B. Given existing debt of $39B, Amgen could finance this deal with debt, but would have to lever up further, which could limit future BD opportunities. Given three major BioPharma bidders, the deal price will be competitive. Amgen may prevail if Horizon is focused on strategic fit, given JnJ's size and Sanofi's European roots."

Guggenheim analysts said they are not surprised by this news as they view Horizon as a "premier biotech company that offers significant growth opportunities across both commercialized and pipeline assets." The analysts highlighted during its September 2021 R&D day, the company noted that 7 products (Tepezza, Krystexxa, Uplizna + 4 pipeline assets) have the potential to generate approximately $10 billion in sales. . Assuming a deal at about 4x sales multiple, they see deal value in the $25-30B range or about $110-$125/share.

Lastly, Stifel analysts think the base business excluding the pipeline is worth at least $125-130 per share. That said they see a value as high as $140 per share after ascribing some value to at least 4 of the ~13 pipeline programs (Daz in SS and Kidney Transplant 35% PoS, Dax in SLE 35% PoS, and HZN-825 in dcSSc 30% PoS).

Shares of Horizon last traded up 31.5% to $103.60 in pre-open trading Wednesday.

Horizon Therapeutics seen worth up to $140/share in takeover
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email